Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation

REFERENCES

• Eschbach JW. Erythropoietin 1991—an overview. Am J Kidney Dis. 1991; 18(Suppl.1)3–9
   PubMedGoogle Scholar
• Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol. 2000; 53: 452–459
   PubMed Web of Science ®Google Scholar
• Memoli B, Minutolo R, Bisesti V, et al. Collaborative Study Group on SMC Membrane. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis. 2002; 39: 266–273
   PubMed Web of Science ®Google Scholar
• Tielemans C, Husson C, Schurmans T, et al. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int. 1996; 49: 236–243
   PubMed Web of Science ®Google Scholar
• Hosoya N, Sakai K. Backdiffusion rather than backfiltration enhances endotoxin transport through highly permeable dialysis membranes. ASAIO Trans. 1990; 36: M311–M313
   Google Scholar
• Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol. 1998; 9: 1314–1317
   PubMed Web of Science ®Google Scholar
• Cappelli G, Tetta C, Canaud B. Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant 2005; 20: 266–270
   PubMedGoogle Scholar
• Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol. 1993; 150: 2007–2017
   PubMed Web of Science ®Google Scholar
• Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colon formation in uremic patients with inflammatory disease. Role of IFN-gamma and TNF-alpha. J Investig Med. 1999; 47: 204–211
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102: 783–788
   PubMed Web of Science ®Google Scholar
• Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110: 1037–1044
   PubMed Web of Science ®Google Scholar
• Fleming RE, Sly WS. Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA. 2001; 98: 8160–8162
   PubMed Web of Science ®Google Scholar
• Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004; 44: 866–876
   PubMed Web of Science ®Google Scholar
• Kausz AT, Solid C, Pereira BJ, Collins AJ. St Peter W. Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease?. Am J Kidney Dis. 2005; 45: 136–147
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl. 2)ii1
   PubMedGoogle Scholar
• NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure. IV. Administration of epoetin. Am J Kidney Dis. 2001; 37(Suppl. 1)S207
   Google Scholar
• Goicoechea M, Martin J, De Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54: 1337–1343
   PubMed Web of Science ®Google Scholar
• Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33: 63–72
   PubMed Web of Science ®Google Scholar
• Lopez-Gomez JM, Perez-Flores I, Jofre R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol. 2004; 15: 2494–2501
   PubMed Web of Science ®Google Scholar
• Nassar GM, Fishbane S, Ayus JC. Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int. 2002; 61(Suppl. 80)49–54
   Google Scholar
• Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int. 2004; 66: 2429–2436
   PubMedGoogle Scholar
• Pecoits-Filho R, Heimbürger O, Bárány P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41: 1212–1218
   PubMed Web of Science ®Google Scholar
• Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2009; 24: 919–925
   PubMed Web of Science ®Google Scholar
• Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol. 2008; 28: 115–121
   PubMed Web of Science ®Google Scholar
• Shinzato T, Abe K, Furusu A, et al. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Med Sci Monit. 2008; 14: CR431–7
   PubMedGoogle Scholar
• Swinkels DW, Wetzels JF. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 2008; 23: 2450–3
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Kartsios C, Liakopoulos V, et al. Does hepcidin affect erythropoiesis in hemodialysis patients?. Acta Haematol. 2006; 116: 238–244
   PubMedGoogle Scholar
• Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009; 75: 976–981
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, O'Neal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13: 1096–1101
   PubMed Web of Science ®Google Scholar
• Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006; 55: 667–674
   PubMed Web of Science ®Google Scholar